CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $115.05M, lower than 95% of all stocks globally
- PositionOperating margin is -8296.3%, lower than 95% of its Biotechnology peers (median -38%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
115.05MUSDvs all stocks (USD)
Revenue (TTM)
190.00KUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.8710xvs all stocks
52-Week Change
31.60%vs all stocks
Market Capitalization
115.05MUSDvs all stocks (USD)
Enterprise Value
63.07MUSDvs all stocks (USD)
Forward P/E
-1.27xvs Biotechnology peers
Price to Book (MRQ)
0.9092xvs Biotechnology peers
Enterprise to Revenue
331.97xvs Biotechnology peers
Enterprise to EBITDA
-1.03xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-20.83%vs Biotechnology peers
Return on Equity (TTM)
-36.21%vs Biotechnology peers
Revenue (TTM)
190.00KUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0020USDUpdated Aug 28, 2026Gross Profit (TTM)
175.00KUSDvs all stocks (USD)
EBITDA (TTM)
-61.35MUSDvs all stocks (USD)
Net Income (TTM)
-56.52MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-50.23MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-29.42MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-66.84MUSDvs all stocks (USD)
Pre-tax Income
-59.00MUSDFY2025 · Dec 31, 2025Net Income
-59.00MUSDFY2025 · Dec 31, 2025EBIT
-66.84MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-60.37MUSDFY2025 · Dec 31, 2025Research & Development
41.11MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
25.73MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
7.87MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-59.00MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-50.45MUSDFY2025 · Dec 31, 2025Free Cash Flow
-51.73MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
13.39MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-59.00MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
6.46MUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.84MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-69.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-4.69MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.28MUSDFY2025 · Dec 31, 2025Purchase of Investments
-72.49MUSDFY2025 · Dec 31, 2025Sale of Investments
108.99MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
35.22MUSDFY2025 · Dec 31, 2025Shares Outstanding
127.22MSharesUpdated Aug 28, 2026Float Shares
58.40MSharesUpdated Aug 28, 2026Shares Short
3.15MSharesUpdated Aug 28, 2026Short Ratio
3.80daysvs all stocks
Short % of Shares Outstanding
5.04%vs all stocks
% Held by Insiders
32.02%vs all stocks
% Held by Institutions
45.23%vs all stocks
Total Cash (MRQ)
84.03MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.6600USDUpdated Aug 28, 2026Total Debt (MRQ)
27.82MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2122xvs Biotechnology peers
Current Ratio (MRQ)
10.14xvs Biotechnology peers
Book Value per Share (MRQ)
1.03USDUpdated Aug 28, 2026Total Assets
191.11MUSDvs all stocks (USD)
Total Current Assets
105.96MUSDFY2025 · Dec 31, 2025Total Liabilities
34.14MUSDFY2025 · Dec 31, 2025Total Non-current Assets
85.15MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
26.19MUSDFY2025 · Dec 31, 2025Total Current Liabilities
7.95MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
12.39MUSDFY2025 · Dec 31, 2025Other Short-term Investments
91.02MUSDFY2025 · Dec 31, 2025Accounts Payable
943.00KUSDFY2025 · Dec 31, 2025Short-term Debt
3.83MUSDFY2025 · Dec 31, 2025Other Current Liabilities
183.00KUSDFY2025 · Dec 31, 2025Long-term Debt
26.19MUSDFY2025 · Dec 31, 2025Common Stock (Book)
13.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-332.02MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
156.97MUSDvs all stocks (USD)
52-Week Low
0.6200USDUpdated Aug 28, 202652-Week High
4.31USDUpdated Aug 28, 202652-Week Change
31.60%vs all stocks
Beta
0.8710xvs all stocks
50-Day MA
1.47USDUpdated Aug 28, 2026200-Day MA
2.19USDUpdated Aug 28, 2026Avg 10-Day Volume
591.81KSharesUpdated Aug 28, 2026Avg 30-Day Volume
792.35KSharesUpdated Aug 28, 2026Diluted EPS (TTM)
-0.4800USDUpdated Aug 28, 2026Other Income / Expense
-32.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -8296.3%, lower than 95% of its Biotechnology peers (median -38%)Significant
Operating margin: -82.96Industry median: -0.38Industry P5: -43.63Peers compared: 260
Price-to-book is 0.91×, lower than 95% of its Biotechnology peers (median 2.86×)Notable
Price-to-book: 0.91Industry median: 2.86Industry P5: 0.98Peers compared: 260
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 10.14Altman Z-Score: -0.95
Financial Health
Altman Z-Score -0.95: distress zoneCritical
Altman Z-Score: -0.95
Low earnings qualitySignificant
Earnings Quality Score: -0.72
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $115.05M, lower than 95% of all stocks globallySignificant
Market cap (USD): 115,051,447Global P5: 275,556,405.438
Revenue is $190,000, lower than 95% of all stocks globallySignificant
Revenue (USD): 190,000Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
3Billion Inc.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
Neumora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Curacle Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Cabio Biotech Wuhan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Intocell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Kala Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Minerva Neurosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Genomictree Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Curocell Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Lyell Immunopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Md Entertainment Tbk
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Wintao Communications Co.
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated